Home / Community / News / News

News

09/22/2016 - 11:33am

Since DM1-related loss of muscle mass confounds a common biomarker of kidney dysfunction, creatinine levels, serum cystatin C provides a superior measure of renal dysfunction for both patient management and clinical trials.

 

09/22/2016 - 11:24am

A recent study corroborated increased susceptibility to cancer in DM1, for women in particular, and linked the elevated risk to depressed levels of a tumor suppressor microRNA (miRNA). 

08/10/2016 - 12:42pm

AMO Pharma Limited (AMO Pharma) today announced initiation of a phase 2 clinical study in the U.K. for AMO-02 (tideglusib).

08/09/2016 - 4:41pm

Dr. Gallais and his team are conducting a longitudinal study of cognition and central nervous system involvement in DM1. Read an interview with Dr. Gallais on this work here.Highlights from IDMC-10

08/09/2016 - 4:30pm

MDF and the Wyck Foundation have awarded new grants to develop phenotypic mouse models of DM as well as new DM1 and DM2 cell lines. Read more about these new partnerships.

Partners

© Myotonic Dystrophy Foundation. All rights reserved.